



Fig 2. Estimated Kaplan-Meier overall survival for patients with advanced non-small-cell lung cancer treated with atezolizumab in the BIRCH trial, by cohort. (A) TC2/3 or IC2/3 group (intent-to-treat population), and (B) TC3 or IC3 subgroup. TC3 or IC3 = TC 50% or IC 10% PD-L1-expressing cells, respectively; TC2/3 or IC2/3 = TC or IC 5% PD-L1-expressing cells, respectively. Cohort 1 = 1L; cohort 2 = 2L; cohort 3 = 3L. On the basis of an updated data cutoff of August 1, 2016. IC, tumor-infiltrating immune cells; NE, not estimable; TC, tumor cells.